Complex therapy of non-alcoholic fatty liver disease in combination with the syndrome of intestinal bacterial overgrowth

2019 ◽  
Vol 0 (1) ◽  
pp. 77-84
Author(s):  
A. E. Dorofeyev ◽  
M. M. Rudenko ◽  
S. M. Tkach ◽  
Yu. Z. Dynia
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Bacterial Overgrowth ◽  
Alcoholic Fatty Liver ◽  
Intestinal Bacterial Overgrowth ◽  
Complex Therapy ◽  
Alcoholic Fatty Liver Disease

scholarly journals Liver disease symptoms in non-alcoholic fatty liver disease and small intestinal bacterial overgrowth

2018 ◽  
Vol 56 (2) ◽  
pp. 85-89
Author(s):  
Rahmatollah Rafiei ◽  
Mahboobeh Bemanian ◽  
Fereshteh Rafiei ◽  
Mahmood Bahrami ◽  
Lotfollah Fooladi ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Bacterial Overgrowth ◽  
Small Intestinal Bacterial Overgrowth ◽  
Alcoholic Fatty Liver ◽  
Intestinal Bacterial Overgrowth ◽  
Significant Difference ◽  
Small Intestinal ◽  
Alcoholic Fatty Liver Disease

Abstract Introduction. It seems that there is a relationship between small intestinal bacterial overgrowth (SIBO) and non-alcoholic fatty liver disease (NAFLD). The main objective of this study was to evaluate the prevalence of SIBO among NAFLD patients. Methods. In this descriptive-analytical cross-sectional study, 98 eligible NAFLD patients were evaluated for SIBO using hydrogen breath test (HBT). They were divided into SIBO-positive and SIBO-negative groups. Demographic, clinical, and laboratory data were obtained. Results. Based on the HBT, 38 patients (39%) had bacteria overgrowth. There were no significant differences between SIBO-positive and SIBO-negative regarding demographic data and BMI classification (P > 0.05). Biochemical variables, the results of abdominal ultrasound, and liver elastography did not show any significant difference between SIBO-positive and SIBO-negative patients (P > 0.05). Patients with SIBO were found to have higher rates of bloating, while abdominal pain was more prevalent in SIBO-negative patients (P < 0.001). Conclusions. SIBO is prevalent in NAFLD and associated with bloating in these patients. Further studies are necessary to elucidate if therapeutic manipulation of gut microbiota reduces the risk of NAFLD, fibrosis, and liver cirrhosis.

scholarly journals Újabb adatok a nem alkoholos zsírmáj patogeneziséhez

2017 ◽  
Vol 158 (23) ◽  
pp. 882-894
Author(s):  
Alajos Pár ◽  
Gabriella Pár
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Cell Injury ◽  
Bacterial Overgrowth ◽  
Small Intestinal Bacterial Overgrowth ◽  
Alcoholic Fatty Liver ◽  
Liver Cell Injury ◽  
Genetic And Environmental Factors ◽  
Alcoholic Fatty Liver Disease

Abstract: Non alcoholic fatty liver disease is the hepatic manifestation of metabolic syndrome, and the most common liver disease. Its more aggressive form is the non alcoholic steatohepatitis. Multiple genetic and environmental factors lead to the accumulation of triglicerides and the inflammatory cascade. High fat diet, obesity, adipocyte dysfunction with cytokine production, insulin resistance and increased lipolysis with free fatty acid flux into the liver – all are the drivers of liver cell injury. Activation of inflammasome by damage- or pathogen-associated molecular patterns results in “steril inflammation” and immune response, while the hepatic stellate cells and progenitor cells lead to fibrogenesis. Small intestinal bacterial overgrowth and gut dysbiosis are also of pivotal importance in the inflammation. Among the susceptible genetic factors, mutations of patatin-like phospholipase domain containing 3 and the transmembrane 6 superfamily 2 genes play a role in the development and progression of the disease, similarly as do epigenetic regulators such as microRNAs and extracellular vesicles. Better understanding of the pathogenesis of non alcoholic fatty liver disease may identify novel therapeutic agents that improve the outcome of the disease. Orv Hetil. 2017; 158(23): 882–894.

scholarly journals Evaluation of the efficiency of Vasonate in patients with comorbid pathology: hypertensive disease and liver steatosis

2018 ◽  
pp. 94-109
Author(s):  
N. V. Kuzminova ◽  
O. V. Gribenyk ◽  
N. Y. Osovskaya ◽  
I. I. Knyazkova
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Liver Steatosis ◽  
Well Being ◽  
Alcoholic Fatty Liver ◽  
Basic Therapy ◽  
Vasomotor Function ◽  
Complex Therapy ◽  
Alcoholic Fatty Liver Disease

The aim of this study was to study the clinical efficacy and safety of the preparation of meldonium Vazonat® as part of the complex therapy of patients with stage II hypertension with comorbid non-alcoholic fatty liver disease. There were 72 patients under examined, the average age was (48.4 ± 1.8) years. Depending on the composition of the combined therapy, patients were separated into 2 groups: the main (38 patients) and comparisons (34 patients). Patients of the main group to the basic therapy, which consisted of modern antihypertensive drugs and statins, were supplemented with meldonium Vasonate preparation 1 capsule (250 mg) 2 times a day for 2 months. Patient comparison groups received only basic therapy. All the examinations were conducted before the appointment of therapy and after 2 months. The study showed that the appointment of complex therapy with the addition of the drug of meldonium Vasonate® not only promotes normalization of the level and daily profile of arterial pressure, a decrease in its variability and recovery of the vasomotor function of the endothelium, but also positively affects most of the indices of lipid, carbohydrate and fat metabolism, can to a certain extent inhibit the development of further metabolic disorders and reduce cardiovascular risk. Due to the complex action on various links and general mechanisms of the pathogenesis of arterial hypertension and non-alcoholic fatty liver disease, the use of meldonium Vazonat® allows optimizing the standart basic therapy, restoring the metabolic status, accompanied by good tolerance, improvement in the well-being, activity and mood of patients.

scholarly journals The importance of the bacterial overgrowth syndrome in the development of disorders metabolic functions of the liver in non-alcoholic fatty liver disease

2021 ◽  
Vol 93 (2) ◽  
pp. 169-173
Author(s):  
Ya. M. Vakhrushev ◽  
A. P. Lukashevich
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Total Protein ◽  
Fatty Liver Disease ◽  
Bacterial Overgrowth ◽  
Control Group ◽  
Alcoholic Fatty Liver ◽  
Overgrowth Syndrome ◽  
Metabolic Functions ◽  
Alcoholic Fatty Liver Disease

Aim. To study the basic metabolic functions of the liver in patients with non-alcoholic fatty liver disease and to assess the relationship of these disorders with the bacterial overgrowth syndrome. Materials and methods. 50 patients with non-alcoholic fatty liver disease at the stage of steatosis were examined. In the verification of the diagnosis, hepatobiliary system ultrasound and FibroMax test data were used. A study was conducted of indicators of lipid, carbohydrate, protein, pigment, mineral metabolism and the exchange of enzymes in the blood. The bacterial overgrowth syndrome was studied by the results of a hydrogen breath test with lactulose using a LactofаH2 analyzer. Results. Patients with non-alcoholic fatty liver disease showed a significant increase in total cholesterol (median 5.9 mmol/l vs 5.0 mmol/l, p=0.000013), triglycerides (1.35 g/l vs 0.9 g/l, p=0.014), glucose (5.65 mmol/l against 5.1 mmol/l, p=0.000001) of blood serum compared with the control group. An increase in total protein and a tendency to decrease in albumin, an increase in serum sodium and calcium were detected. In patients with non-alcoholic fatty liver disease there is a significant increase in the markers of cytolysis and cholestasis compared with the control group. The bacterial overgrowth syndrome was detected in 72% of cases, with ileocecal valve function impaired in 50% of patients, gastrointestinal motility slowed down, or colon dysbiosis occurred. A correlation analysis revealed positive relationships between the bacterial overgrowth syndrome on the one hand and glucose (r=0.83, p0.05), total protein (r=0.35, p0.05), calcium (r=0.5, p0.05) on the other hand; negative relationship between the bacterial overgrowth syndrome and albumin (r=-0.8, p0.05). In this case, a positive relationship between the bacterial overgrowth syndrome and the increase in glycemia after glucose loading, that is, absorption in the small intestine, was revealed. Conclusion. The established violations of the metabolic functions of the liver with non-alcoholic fatty liver disease are closely related to the bacterial overgrowth syndrome.

Sign in / Sign up

Export Citation Format

Share Document